Washington University School of Medicine

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Washington University School of Medicine sits in the top decile of US sponsors by registered trial count (#12 of 15,742 sponsors by registered trial count).

1,502 total trials 214 currently recruiting 919 completed early-phase tilt top decile by trial count

Washington University School of Medicine: 1,502 sponsored US clinical trials, 214 recruiting.

Washington University School of Medicine sponsors 1,502 registered US clinical trials on ClinicalTrials.gov, 214 of them currently recruiting, and 919 completed. 98 of these trials are in Phase 3-4 (later-stage) and 569 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 20 trials.

Top-decile sponsor footprint

Washington University School of Medicine ranks in the top decile of sponsors by registered trial count (#12 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 38/100

919 of 1,159 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (79.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,502 total, page 14 of 31

COMPLETED Phase 2

Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

NCT03623373
COMPLETED

Functional Imaging Reserve in NeuroHIV

NCT03596268
TERMINATED Early Phase 1

64Cu-LLP2A for Imaging Multiple Myeloma

NCT03804424
COMPLETED NA

Motor Learning Approach for Manual Wheelchair Users

NCT03781609
TERMINATED Phase 1

Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

NCT03422094
COMPLETED NA

Metabolic Effects of Sleep Extension in People With Obesity

NCT03594994
COMPLETED Early Phase 1

Analysis of Antigen Specific B Cell Responses to Immunization With Influenza Virus Vaccine

NCT03748524
COMPLETED NA

Exercise Training and Manual Wheelchair Users With SCI

NCT03727893
COMPLETED

Postoperative Delirium: EEG Markers of Sleep and Wakefulness

NCT03291626
TERMINATED Phase 1

Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma

NCT03121677
COMPLETED Early Phase 1

Assessment and Management of Chronic Dyspepsia in Eastern Uganda

NCT04525664
TERMINATED NA

Glucose Uptake in Metabolic Tissues After Bariatric Surgery

NCT03563885
COMPLETED NA

Translation of Pritikin Program to the Community

NCT03929198
COMPLETED NA

A New Method for Identifying Sensory Changes in Painful Chemotherapy-induced Peripheral Neuropathy (CIPN)

NCT03687970
COMPLETED Phase 1

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

NCT03532217
TERMINATED Phase 1

Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors

NCT03511222
TERMINATED NA

Glucose Time-In-Range Development Evaluation

NCT03670017
COMPLETED NA

High Risk Youth With Poorly-controlled Diabetes

NCT03680079
COMPLETED Phase 1

BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

NCT03496662
COMPLETED

I-Tracking Neurodegeneration in Early Wolfram Syndrome

NCT03951298
COMPLETED

An Observational Study of Integrated Chronic Pain Management in a Community Health Center

NCT04490291
COMPLETED NA

Adapted Lifestyle-integrated Functional Exercise Program for Medically Underserved Older Adults

NCT03704194
COMPLETED NA

Intrapartum Maternal Oxygen Supplementation: Effects on the Mother and Neonate

NCT03581214
COMPLETED Phase 2

Does Antibiotic Prophylaxis Reduce Wound Complications After Vulvar Excision of Premalignant Lesions

NCT03578965
COMPLETED

Management of Malignant Pleural Effusions Using an Indwelling Tunneled Pleural Catheter and Non-Vacuum Collection System

NCT03414905
COMPLETED NA

Interactive Obesity Treatment Approach (iOTA) for Obesity Prevention in Serious Mental Illness

NCT03695289
COMPLETED NA

Evaluating and Improving the Sustainability of State-level Tobacco Control Programs in the United States

NCT03598114
COMPLETED NA

Improving Cancer Patients' Insurance Choices

NCT03592433
COMPLETED NA

Brain Stimulation and Enhancing Cognition in Older Adults

NCT03653351
COMPLETED Phase 4

Defining Predictors of RT Response to Vedolizumab in IBD

NCT03142321
TERMINATED Phase 4

Once Daily Immunosuppression Regimen

NCT03555448
COMPLETED Early Phase 1

RANKL Inhibition and Breast Tissue Biomarkers

NCT03629717
TERMINATED NA

Dual-Energy CT on Plan Quality, Dose-delivery Accuracy, and Simulated Outcomes of Patients Treated With Proton or Photon Therapy

NCT03403361
COMPLETED NA

Hormonal Contraceptive Health Education for Adolescent Males

NCT03400410
COMPLETED Phase 1

Ready to Use Therapeutic Food (RUTF) to Promote Growth in Cystic Fibrosis

NCT03462056
COMPLETED Phase 1

Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation

NCT03207958
COMPLETED

Prematurity-Related Ventilatory Control

NCT03464396
COMPLETED Phase 2

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer

NCT03449901
COMPLETED Phase 1

Psychological Services Integration in Gynecological Oncology Clinics

NCT03481127
TERMINATED Phase 4

Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder

NCT03537547
TERMINATED NA

Chronic Stroke Rehabilitation With Contralesional Brain-Computer Interface

NCT03611855
TERMINATED Phase 1

Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis

NCT03386214
TERMINATED Phase 1

Body Scan Activity on Bone Marrow Transplant Patients and Their Caregivers

NCT03611764
COMPLETED

Effect of SB CD on Chylomicron

NCT03496818
COMPLETED NA

iTBS Study for Depression (Randomized)

NCT03745768
COMPLETED NA

A Wheelchair Propulsion Training Program

NCT04009187
TERMINATED Phase 2

Nutraceutical Efficacy for rUTI

NCT03395288
COMPLETED NA

Supporting Patient Decisions About UE Surgery in Cervical SCI

NCT03464409
TERMINATED NA

Ultrasound and Photoacoustic Imaging for Cervical Cancer

NCT03318107
COMPLETED Phase 1

Fecal Microbiota Transplantation (FMT) for MDRO UTI

NCT03367910
← Previous Page 14 of 31 Next →

Phase Distribution

PhaseTrial count
Phase 1 332
Phase 2 237
Phase 3 40
Phase 4 58

Therapeutic Areas

Obesity 20
Breast Cancer 19
Multiple Myeloma 13
Myelodysplastic Syndromes 13
Alzheimer Disease 10
Parkinson Disease 8
Depression 8
Cancer of the Breast 7
Dementia 7
Insulin Resistance 7

What is open in the Washington University School of Medicine pipeline

214 recruiting of 1,502 indexed (14% open); 919 completed (61%).

Phase mix: 98 late (III/IV) vs 569 early (I/II) (early-phase heavy).

Top condition: Obesity (20 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Washington University School of Medicine: open-pipeline peers nationwide

Peers matched on 1,502 registered trials and 14% open enrollment, not the therapeutic-area sidebar.

Washington University School of Medicine sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share Washington University School of MedicineYale UniversityJohns Hopkins UniversityUniversity of PennsylvaniaNovartis PharmaceuticalsAcademic and Community Cancer Research UnitedAdaptive BiotechnologiesAgelessRxAlaska Blind Child Discovery
Washington University School of Medicine sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Washington University School of Medicine sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,502 trials (± recruiting share)

Sponsors near 14% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Washington University School of Medicine page

1,502 registered trials is a research-attention snapshot, not an endorsement of Washington University School of Medicine or any single study.

  • 214 of Washington University School of Medicine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition Washington University School of Medicine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Washington University School of Medicine pipeline card: 1,502 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.